Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer

Background: Tyrosine kinase inhibitors (TKIs) have significantly improved treatment-related outcomes of patients with oncogene-driven non-small-cell lung cancer (NSCLC). TKIs are usually well tolerated and used for a prolonged time, although experienced toxicity varies between patients. It is unclea...

Full description

Bibliographic Details
Main Authors: Judith Gulikers, Jeroen Bruinsma, Janna Schoenmaekers, Safiye Dursun, Vivianne Tjan-Heijnen, Robin van Geel, Sander Croes, Lizza Hendriks
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359241303403

Internet

https://doi.org/10.1177/17588359241303403

Similar Items